Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
Neuroblastoma is the most common extracranial solid tumor in infants and young children. Current treatments are not always effective and new therapies are needed. We examined efficacy of combination of the small molecule Bcl-2 inhibitor HA14-1 (HA) and the dietary isoflavonoid apigenin (APG) in human malignant neuroblastoma cells. Dose-response studies indicated that treatment with HA and APG for 24 h synergistically reduced cell viability in human malignant neuroblastoma SK-N-DZ, SH-SY5Y, and IMR32 cells. For further studies, we selected SK-N-DZ cells that showed the highest sensitivity following treatment with 2.5 microM HA, 100 microM APG, or combination (2.5 microM HA+100 microM APG). Wright staining showed increase in morphological features of apoptosis. Cell cycle distribution and Annexin V assay showed that combination therapy caused more apoptosis than either treatment alone. Western blotting revealed that combination therapy downregulated angiogenic factors and also induced extrinsic pathway of apoptosis with activation of caspase-8 for Bid cleavage to tBid. Alterations in Bax and Bcl-2 levels resulted in an increase in Bax:Bcl-2 ratio to activate intrinsic pathway of apoptosis with mitochondrial release of cytochrome c into the cytosol and activation of proteases. Increases in calpain and caspase-3 activities generated 145 kD spectrin break down product (SBDP) and 120 kD SBDP, respectively. Results showed that combination of HA and APG could be used for downregulation of angiogenic factors and activation of extrinsic and intrinsic pathways of apoptosis in malignant neuroblastoma cells.
Karmakar
Surajit
S
Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA.
Davis
Kristin A
KA
Choudhury
Subhasree Roy
SR
Deeconda
Anurag
A
Banik
Naren L
NL
Ray
Swapan K
SK
D024221:Antineoplastic Protocols; D047310:Apigenin / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001578:Benzopyrans / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009447:Neuroblastoma / Q000188:drug therapy*; D009570:Nitriles / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D001578:Benzopyrans; D009570:Nitriles; D019253:Proto-Oncogene Proteins c-bcl-2; D042461:Vascular Endothelial Growth Factor A; C456800:ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate; D047310:Apigenin; D066246:ErbB Receptors
Cancer Lett. 2005 Apr 28;221(2):153-63
15808401
Prostate. 2005 May 1;63(2):131-42
15486995
Free Radic Biol Med. 2008 May 15;44(10):1833-45
18342637
Toxicol In Vitro. 2009 Aug;23(5):797-807
19397994
Nature. 1999 Jun 3;399(6735):483-7
10365962
Cancer. 2005 Apr 15;103(8):1551-60
15742333
Cancer Res. 1994 Jun 15;54(12):3253-9
8205548
Toxicology. 2006 Jan 16;217(2-3):206-12
16289292
Mol Cancer Ther. 2002 Oct;1(12):961-7
12481420
J Biol Chem. 2003 Apr 18;278(16):14162-7
12576481
Oncol Rep. 2007 Feb;17(2):465-9
17203189
Int J Oncol. 2009 Mar;34(3):757-65
19212680
Front Biosci. 2007 Jan 01;12:1935-45
17127432
Int J Cancer. 2006 Dec 1;119(11):2575-85
16988947
Clin Cancer Res. 2004 Dec 15;10(24):8284-92
15623604
Oncogene. 2007 Feb 1;26(5):652-61
16909121
Pancreas. 2009 May;38(4):409-15
19142175
J Pediatr Surg. 2002 Mar;37(3):467-71
11877669
Anticancer Res. 1999 Sep-Oct;19(5B):4297-303
10628390
Cancer Res. 2006 Mar 1;66(5):2757-64
16510597
J Nutr Biochem. 2009 Apr;20(4):285-90
18656338
Clin Cancer Res. 2007 Dec 15;13(24):7254-63
18094405
J Pediatr Surg. 1995 Jun;30(6):805-8
7666311
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9
10860979
Nat Rev Cancer. 2003 Mar;3(3):203-16
12612655
Mol Nutr Food Res. 2008 May;52(5):507-26
18435439
Neuroscience. 2006 Sep 1;141(3):1265-80
16765523
Int J Oncol. 2009 Feb;34(2):401-7
19148474
Clin Cancer Res. 2004 May 1;10(9):3169-78
15131058
Oncogene. 2002 May 23;21(23):3727-38
12032841
Curr Opin Mol Ther. 2009 Jun;11(3):308-21
19479664
Science. 1998 Aug 28;281(5381):1309-12
9721092
Nature. 1998 Jan 1;391(6662):96-9
9422513
J Clin Biochem Nutr. 2009 May;44(3):260-5
19430615